Toni Weinschenk
Fortune : - $ au 31/05/2026
Fortune : - $ au 31/05/2026
Toni Weinschenk is the founder of Immatics Biotechnologies GmbH, founded in 2000, holding the title of Chief Innovation Officer since 2020.
Dr. Weinschenk is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Technology Officer since 2015.
Dr. Weinschenk currently holds the position of Chief Innovation Officer at Immatics NV since 2020.
Dr. Weinschenk earned a doctorate from Eberhard Karls Universität Tübingen.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V. -.--% | 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01/01/2020 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Fondateur | 01/01/2000 |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Fondateur | 01/06/2015 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national